The use of bioresorbable vascular scaffold Absorb BVS® in patients with stable coronary artery disease: one-year results with special focus on the hybrid bioresorbable vascular scaffolds and drug eluting stents treatment.
The number of percutaneous coronary interventions (PCI) with bioresorbable vascular scaffolds (BVS) is in-creasing because these procedures offer additional benefits compared to PCI with classical drug eluting stents (DES) made of permanent metallic prostheses. To present the current experience of using BVS in a real life scenario in patients with stable coronary artery disease (CAD), with a special focus on the assessment of safety and effectiveness of the hybrid strategy (single stage BVS and DES implantation). We performed a one-arm prospective registry, which enrolled patients with stable CAD in five interventional cardiology centres in Poland. All patients who met inclusion and exclusion criteria and had received at least one BVS stent during index PCI were included. The primary endpoint was the cumulative rate of major adverse cardiovascular events (MACE), consist-ing of cardiac death, myocardial infarction (MI), and clinically-driven target lesion revascularisation (TLR) at 12 months. The analysis was performed in the whole population as well as in the subgroup with the hybrid treatment (BVS + DES). Between August 2013 and April 2014 139 patients were enrolled. The mean age was 59.5 ± 5.5 years, and 34.5% of the population were women. The target vessel was located in the left anterior descending artery in most cases (65.5%). The device success rate was 100%. At 12 months, in the whole population the cumulative MACE incidence was 7.2% (n = 10), while the clinically-driven TLR rate was 5.0% (n = 7). In further analysis, in the hybrid subgroup there was no death, MI, or stent thrombosis, and only one case of clinically-driven TLR (4.5%). The obtained data enable us to say that in particular clinical scenarios the simultaneous use of BVS and DES might be safe and effective.